Stock Track | ImmunityBio, Inc. Shares Plummet 5.09% as Earnings Disappoint Despite EPS Beat

Stock Track

Mar 04, 2025

ImmunityBio, Inc. (NASDAQ: IBRX) shares plummeted 5.09% during Tuesday's intraday trading session, following the company's release of its Full Year 2024 financial results. Despite beating earnings per share (EPS) expectations, the biotechnology firm's revenue fell short of analyst estimates, weighing on investor sentiment.

According to the report, ImmunityBio generated revenue of $14.7 million for the fiscal year 2024, up from $0.6 million in the previous year but missing analysts' forecasts by 31%. However, the company reported a narrower net loss of $413.6 million, translating to an EPS loss of $0.59, which exceeded expectations by 26%.

While ImmunityBio's revenue growth trajectory remains strong, with a projected 55% annualized increase over the next three years, investors appear to have reacted negatively to the missed revenue target. The company's shares are now down 11% from a week ago.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173918028"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173918028\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173918028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 23:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173918028","market":"hk","top_or_hot":-1,"title":"Stock Track | ImmunityBio, Inc. Shares Plummet 5.09% as Earnings Disappoint Despite EPS Beat","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ: IBRX) shares plummeted 5.09% during Tuesday's intraday trading session, following the company's release of its Full Year 2024 financial results. Despite beating earnings per share (EPS) expectations, the biotechnology firm's revenue fell short of analyst estimates, weighing on investor sentiment.</p>\n\n<p>According to the report, ImmunityBio generated revenue of $14.7 million for the fiscal year 2024, up from $0.6 million in the previous year but missing analysts' forecasts by 31%. However, the company reported a narrower net loss of $413.6 million, translating to an EPS loss of $0.59, which exceeded expectations by 26%.</p>\n\n<p>While ImmunityBio's revenue growth trajectory remains strong, with a projected 55% annualized increase over the next three years, investors appear to have reacted negatively to the missed revenue target. The company's shares are now down 11% from a week ago.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio, Inc. Shares Plummet 5.09% as Earnings Disappoint Despite EPS Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio, Inc. Shares Plummet 5.09% as Earnings Disappoint Despite EPS Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-04 23:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ: IBRX) shares plummeted 5.09% during Tuesday's intraday trading session, following the company's release of its Full Year 2024 financial results. Despite beating earnings per share (EPS) expectations, the biotechnology firm's revenue fell short of analyst estimates, weighing on investor sentiment.</p>\n\n<p>According to the report, ImmunityBio generated revenue of $14.7 million for the fiscal year 2024, up from $0.6 million in the previous year but missing analysts' forecasts by 31%. However, the company reported a narrower net loss of $413.6 million, translating to an EPS loss of $0.59, which exceeded expectations by 26%.</p>\n\n<p>While ImmunityBio's revenue growth trajectory remains strong, with a projected 55% annualized increase over the next three years, investors appear to have reacted negatively to the missed revenue target. The company's shares are now down 11% from a week ago.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1173918028","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173918028","pubTimestamp":1741101642,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc.  shares plummeted 5.09% during Tuesday's intraday trading session, following the company's release of its Full Year 2024 financial results. Despite beating earnings per share  expectations, the biotechnology firm's revenue fell short of analyst estimates, weighing on investor sentiment.According to the report, ImmunityBio generated revenue of $14.7 million for the fiscal year 2024, up from $0.6 million in the previous year but missing analysts' forecasts by 31%. However, the co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"股票追踪ImmunityBio,Inc.股价暴跌5.09%，尽管每股收益超出预期，但盈利令人失望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ: IBRX) shares plummeted 5.09% during Tuesday's intraday trading session, following the company's release of its Full Year 2024 financial results. Despite beating earnings per share (EPS) expectations, the biotechnology firm's revenue fell short of analyst estimates, weighing on investor sentiment.\nAccording to the report, ImmunityBio generated revenue of $14.7 million for the fiscal year 2024, up from $0.6 million in the previous year but missing analysts' forecasts by 31%. However, the company reported a narrower net loss of $413.6 million, translating to an EPS loss of $0.59, which exceeded expectations by 26%.\nWhile ImmunityBio's revenue growth trajectory remains strong, with a projected 55% annualized increase over the next three years, investors appear to have reacted negatively to the missed revenue target. The company's shares are now down 11% from a week ago.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}